Kaiser, Martin
Beksaç, Meral
Gulbrandsen, Nina
Schjesvold, Fredrik
Hájek, Roman
Moreau, Philippe
de Arriba de la Fuente, Felipe
Mateos, María-Victoria
West, Sharon
Spencer, Andrew
Rajkumar, S. Vincent
Suryanarayan, Kaveri
Czorniak, Michael
Li, Cong
Teng, Zhaoyang
Labotka, Richard
Dimopoulos, Meletios A.
Funding for this research was provided by:
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 12 May 2020
Accepted: 14 June 2020
First Online: 1 July 2020
Change Date: 27 October 2020
Change Type: Correction
Change Details: Low-resolution figures were inadvertently created during production and published.
Compliance with ethical standards
:
: MK: consulting/advisory relationship with Abbvie, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, and Takeda; research funding from Celgene and Janssen; honoraria from Celgene, Janssen, Amgen, and TakedaMB: consulting/advisory relationship with Amgen, Takeda, Bristol Myers Squib, Janssen & Janssen, and Sanofi, and honoraria received indirectly through the institutions for these consultancies; scientific advisory boards with Amgen, Takeda, BMS, Janssen & Janssen, and SanofiNG: nothing to discloseFS: consulting/advisory relationship with Mundipharma, GSK, Pfizer/BMS, Novartis, Amgen, Celgene, Takeda, Bayer, Adaptive, Janssen, Oncopeptides, and MSD, Sanofi; research funding from Celgene, Mundipharma, Amgen, Novartis, Takeda, and Janssen; honoraria from Amgen, Mundipharma, Celgene, Teva, BMS, Takeda, Abbvie, Janssen, Novartis, and SkyliteDX; ownership interests with OncopeptidesRH: consulting/advisory relationship with Janssen, Amgen, Celgene, Abbvie, BMS, Novartis, Pharma Mar, and Takeda; research funding from Janssen, Amgen, Celgene, Abbvie, BMS, Novartis, and Takeda; honoraria from Janssen, Amgen, Celgene, Abbvie, BMS, Novartis, Pharma Mar, and TakedaPM: consulting/advisory relationship with Takeda, Amgen, Celgene, Janssen, and Abbvie; honoraria from Takeda, Amgen, Celgene, Janssen, and AbbvieFdA: honoraria from Celgene, Amgen, Janssen, and Takeda; scientific advisory board with Celgene, Amgen, and JanssenM-VM: honoraria from Janssen, Celgene, Amgen, Takeda, Abbvie, GSK, Adaptive, EDO Mundipharma, Roche, and Seattle Genetics; scientific advisory board with Janssen, Celgene, Amgen, Takeda, Abbvie, GSK, Adaptive, EDO Mundipharma, Roche, and Seattle GeneticsSW: nothing to discloseAS: nothing to discloseSVR: nothing to discloseKS: employee of Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company LimitedMC: employee of Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company LimitedCL: employee of and ownership interests in Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company LimitedZT: employee of Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company LimitedRL: employee of Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company LimitedMAD: honoraria from Amgen, Janssen, Takeda, Celgene, and BMS; consulting or advisory role with Amgen, Janssen, Takeda, Celgene, and BMS
: TOURMALINE-MM3 was conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and all relevant regulatory requirements. The protocol was approved by an ethics committee/institutional review board at each center.
: Informed consent was obtained from all patients for being included in the study.
: The authors provided informed consent to publish.